Medicare Copays For New Alzheimer's Drug Could Reach $11,500 Annually
Published
Some advisors to the Food and Drug Administration have quit over the drug which critics say has questionable benefits. The FDA said it can reduce clumps of plaque in the brain and may slow dementia.
Full Article